Article Sidebar

Submitted
Apr 15, 2021
Published
Apr 15, 2021
Download
PDF
Statistic
Read Counter : 70 Download : 65

Main Article Content

Abstract

Drug interactions are widely an important source of medication errors.Recently, potentially serious drug-drug interactions among medication errors has achieved significant clinical importance.An interaction is said to occur when the effect of one drug is changed by the presence of another drug, food or environmental chemical changes.Many of the drug interactions can be predictable; if the prescriber updates the knowledge with clinical pharmacology they can be avoided.Monitoring safety and effectiveness and evaluating the patient’s response to therapy.To identify and prevent drug related problems like adverse drug events by conducting a comprehensive medication review.Warfarin with Antimicrobials (Amoxycillin, Ampicillin, Ciprofloxacin, Nitrofurantoin) -  may have risk for upper Gastrointestinal bleeding and the interaction occurs prior to 14 days of administration.


Drug interactions are considered as one of the major important factor for the occurrence of negative outcomes like adverse drug events. So, drug interactions cannot be neglected and should be considered seriously. Patient should be monitored closely for adverse drug reactions.

Keywords

Drug interactions Drugs Food

Article Details

How to Cite
Dr. G. RamyaBalaprabha, Sai Mahitha, Aparna, Vikas Patnaiak, Sikha Singh, Dr.Sharadha. R, & Dr. K. Abbulu. (2021). A review on essentials of drug interactions. International Journal of Research in Pharmacology & Pharmacotherapeutics, 6(2), 117-126. https://doi.org/10.61096/ijrpp.v6.iss2.2017.117-126
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1]. Sandson N. Drug-drug interaction: the silent epidemic. Psychiatric Services 56(1), 2005, 22-4.
  2. [2]. Jankel CA and Speedie SM. Detecting drug interactions: a review of the literature. DICP. 24, 1990, 982-89.
  3. [3]. Merlo J, Liedholm H, Lindblad U, Bjorck-Linne A, Falt J, Lindberg G, Melander A. Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999: cross sectional study. BMJ. 323(7310), 2001, 427-428.
  4. [4]. Kappa PA, Klop AC, Jenkins LS, Drug interactions in primary health care in the George subdistrict, South Africa: a cross-sectional study. South AfrFamPract 55(1), 2013, 78-84.
  5. [5]. Grattagliano I, Portineasa P, D’Ambrosio G, Palmieri VO, Palaseiano G. Avoiding drug interactions; here’s help. J FamPract 59, 2010, 322-329.
  6. [6]. Peng CC, Glassman PA, Marks IR, Powler C, Castigliene B, Good CB, Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population, J Manag Care Pharm. 9(6), 2003, 513-522.
  7. [7]. Zwart-Van-Rijkom JEF. Uijtendaal EV, Ten Berg MJ, VanSolinge WW, Erberts ACG, Frequency and nature of drug-drug interactions in a Dutch university hospital. Br J ClinPharmacol 68, 2009, 187-193.
  8. [8]. Wiesner C, Hersberger KE, Surber C, Haefeli WE. Drug safety after hospital discharge. Pharm World Sci. 22, 1999, A18.
  9. [9]. Lee A, Stockley IH. Drug interactions In Walker R, Edwards C. Clinical pharmacy and Therapeutic, 3rd edition. Churchill Livingstone, Philadelphia 2003, 21-31.
  10. [10]. Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet 370, 2007, 185-91
  11. [11]. Horn JR, Hansten PD, Chan LN Proposal for a new tool to evaluate drug interaction cases. Annals of Pharmacotherapy, 41, 2007, 674-680.
  12. [12]. Jha AK. Kuperman GJ, Rittenberg E, Teich JM and Bates DW. Identifying hospital admissions due to adverse drug events using a computer-based monitor. Pharmaoepidemiol Drug saf. 10, 2001, 113-119.
  13. [13]. Stockley I H. Drug interaction: a source book of adverse interaction, their mechanisms, clinical importance and management. pharmaceutical press, London 5, 1999.
  14. [14]. Gaeta TJ, Fiorini M, Ender K, Bove J, Diaz J. Potential drug-drug interactions in elderly patients presenting with syncope. J Emerg Med. 22, 2002, 159-62.
  15. [15]. Quinn DI, Day RO. Clinically important drug interactions. In: Speight TM, Holford HG, editors, Avery’s Drug treatment, Auckland (New Zealand): Adis International; 1997, 301-38.
  16. [16]. May FE, Stewart RB, Cluff LE. Drug interactions and multiple drug administration. ClinPharmacolTher 22, 1977, 322-8
  17. [17]. Oates JA. The science of drug therapy. In: Brunton LL, ed. Goodman and Gilman’s The pharmacological Basis of Therapeutics. 11thed. New York: McGraw-Hill; 2006.
  18. [18]. Madhav M, Sanghavi D, Review of drug interactions: A Comprehensive Update. British Journal of Pharmaceutical Research 4(8), 2014, 954-80.
  19. [19]. Cupp MJ. Herbal Remedies: adverse effects and drug interactions.AmFam Physician 1999;59(5):1239-45.
  20. [20]. Kruthi P, Brosi E, Fux R et al. Ginger-associated overanticoagulation by phenprocoumon. Ann Pharmacother 38, 2004, 257-60.
  21. [21]. Segura-Bedmar I, Martinez P, de Pablo- Sanehez C. Extracting drug-drug interactions from biomedical texts. BMC Bioinformatics 1(5), 2010, 9.
  22. [22]. Brackett CC, Bloch JD, Phenytoin as a possible cause of acetaminophen hepatotoxicity: case report and review of the literature. Pharmacotherapy 20, 2000, 229-33.
  23. [23]. Cassano WF, Serious methotrexate toxicity caused by interaction with ibuprofen (letter). Am J PediatrHematolOncol 11, 1989, 481-2.
  24. [24]. Cruciol-Souza JM, Thomson JC, A pharmacoepidemiologic study drug interactions in a Brazilian teaching hospital. Clinics 61(6), 2006, 515-20.
  25. [25]. Akshaya SB et al. Prevalence of potential drug-drug interactions among internal medicine ward in university of Gondar teaching hospital. Asian pacific journal of tropical biomedicine 4(1), 2014, S204-8
  26. [26]. Pratibha M, Drug Interactions-Causes and Implications. Research and Review: Journal of Pharmacy and Pharmaceutical Sciences 2(3), 2013, 101-5
  27. [27]. Quintas LEM, Gram KRS, da Silveira GPE et al.Pharmacokinetic Modifications and Drug-Drug Interactions in Clinical Monitoring of the Elderly: A Short Review. Pharm Anal Acta 2, 2011, 141.
  28. [28]. Ferdous S, Sultan MZ, Bashar T et al. Invitro and Invivo Studies of Drug-Drug interaction between Metformin and Cefepime. Pharm Anal Acta; 6, 2015, 348.
  29. [29]. Hussar DA, Drug interaction, In: Gennaro, Marderosian AHD, Hanson GR et al. Remington The science and practice of pharmacy. Philadelphia: Lippincott Williams and Willinks 2000, 174-61.
  30. [30]. Thomas A, Routledge PA. Drug interaction in clinical practice. Focus.Quarterly bulletin of pharmacovigilance. 2003.
  31. [31]. Caterina P, Antonella DP, Chiara G et al. Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci 18, 2013, 600-9.
  32. [32]. Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. New Delhi: McGraw Hill, Lange. Tata McGraw-Hill Edition; 12, 2012.
  33. [33]. Tripati KD. Essentials of Medical Pharmacology. New Delhi: Jaypee Brothers Medical Publishers; 7, 2013.
  34. [34]. Possi A, Gallelli L. Pain management for dentists: the role of ibuprofen. Ann Stomatol (Roma) 2(3-4), 2011, 3-24.
  35. [35]. Patane M, Ciriaco M, Chimirri S et al. Interactions among low dose of methotrexate and drugs used in the treatment of rheumatoid arthritis. AdvPharmacolSci 2013.
  36. [36]. Shimada T, Yamazaki H, Mimura M, et al.Interindividual variations in human liver cytochrome P-450 enzymes involved in oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians, J PharmacolExpTher.270(1), 1994, 414-23.
  37. [37]. Forrester LM, Henderson CJ, Glancey MJ et al. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J. 281(2), 1992, 359-68.
  38. [38]. Caranasos GJ, Stewart RB, Cluff LE. Clinically Desirable Drug Interactions. Ann Rev PharmacolToxicol. 25, 1985, 67-95.
  39. [39]. Brown HS, Galetin A, Hallifax D et al. Prediction of In vivo drug-drug interactions from In vitro data: factors affecting prototype drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinetic. 45(10), 2006, 1035-50.
  40. [40]. Von Moltke LL, Greenblatt DJ, Schmider J et al. In vitro approaches to predicting drug interactions in vivo. BiochemPharmacol. 55(2), 1998, 113-22.
  41. [41]. Drug interactions studies- Study design, data analysis, implications for dosing and labelling recommendations. Draft guidance for industry. US Department of Health and Human Services Food and Drug Administration Centre for Drug Evaluation and Research. 2012, 1-75.
  42. [42]. Bista D, Palaian S, Shankar PR et al. Understanding the essentials of drug interactions: A potential need for safe and effective use of drugs. Kathmandu University Medical Journal. 4(3), 2006, 421-30.
  43. [43]. Ansari JA. Drug interaction and pharmacist. J Young Pharm 3, 2010, 326-31.
  44. [44]. Kashif S, Syed YH, Faizan S, Ansari JA. Drug interaction: A brief of preventive approaches. IJUPLS 2(3), 2012, 422-7.
  45. [45]. Pasternak RC et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am CollCardiol 40(3), 2002, 567-72.
  46. [46]. Fischer HD, Juurlink DN, Mamdani MM et al. Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study. Arch Intern Med. 170, 2010, 617-21.
  47. [47]. Antoniou T, Gomes T, Mamdani MM etal.Ciprofloxacin-induced theophylline toxicity: a population-based study. Eur J ClinPharmacol, 67, 2011, 521-26.
  48. [48]. Schelleman H, Bilker WB, Brensinger CM et al. Anti-infectives and the risk of severe hypoglycaemia in users of glipizide or glyburide. ClinPharmacolTher. 88, 2010, 14-22.
  49. [49]. Chan AL, Wang MT, Su CY et al. Risk of digoxin intoxication caused by clarithromycin-digoxin interactions in heart failure patients: a population-based study.Eur J ClinPharmacol. 65, 2009, 1237-43.
  50. [50]. Kelly CM, Juurlink DN, Gomes T et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving ramoxifen: a population based cohort study. British Medical Journal. 340, 2010, c693.
  51. [51]. Juurlink DN, Mamdani M, Kopp A et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. Journal of the American Medical Assocation. 289, 2003, 1652-58.
  52. [52]. Wright AJ, Gomes T, Mamdani MM et al. The risk of hypotension following co-prescription of macrolides antibiotics and calcium-channel blockers. Canadian Medical Association Journal. 183, 2011, 303-7.